Recently BRAF V600E mutant-specific antibody (clone VE1) became available to immunohistochemically pinpoint the occurrence of these BRAF-mutant proteins in different tumors, such as colon carcinoma. Detection of BRAF mutations is important for the accurate application of targeted therapy against BRAF serine-threonine kinase activation. In this study, we evaluated 113 colon carcinomas including 95 primary and 27 metastatic tumors with the VE1 antibody using Leica Bond-Max automated immunohistochemistry. To ensure comprehensive BRAF V600E mutation detection, all cases were evaluated using 4 molecular methods (Sanger sequencing, the Cobas 4800 BRAF V600 Mutation Test, BRAF V600 allele-specific polymerase chain reaction, and BRAF V600 quantitative polymerase chain reaction) with nearly 100% concordance. Molecular and immunohistochemical studies were blinded. Furthermore, all cases were evaluated for KRAS and NRAS mutations as parameters mutually exclusive with BRAF mutations offering parallel evidence for BRAF mutation status. Strong to moderate VE1 positivity was seen in 34 tumors. Twelve colon carcinomas showed weak VE1 immunohistochemical staining, and 67 were entirely negative. An identical c.1799T > A single nucleotide substitution leading to the BRAF V600E mutation was identified in 27 of 113 (24%) colon carcinomas. A majority of BRAF-mutant tumors were located in the right side of the colon and had mismatchrepair deficiency. V600E mutation-negative carcinomas were more often sigmoid tumors and usually showed intact mismatchrepair proteins and KRAS or NRAS mutations. The sensitivity and specificity of positive results (strong to moderate staining) of VE1 immunohistochemistry were 85% and 68%, respectively. If any positivity would be considered, then the specificity declined to 51% with no significant improvement of sensitivity. Therefore, only strong positivity should be considered when using the VE1 antibody and Leica Bond-Max automated immunohistochemistry with these parameters. Although VE1 antibody can be useful in the screening of colon carcinomas for BRAF V600E-mutant proteins, molecular genetic confirmation is always necessary for mutation diagnosis.
B RAF gene encodes a serine/threonine-protein kinase B-Raf (BRAF), which belongs to the family of growth signal transduction nonreceptor protein kinases. Oncogenic activation of BRAF leads to constitutive kinase activity and phosphorylation of downstream targets of the RAS/RAF/ MAPK signaling pathway. 1 Gain-of-function BRAF mutations have been identified in different types of cancer, such as colon carcinoma, melanoma, papillary thyroid carcinoma, and some lymphomas, among others, as listed by COSMIC, the catalog of somatic mutations in cancer (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/).
In colon carcinoma, the most common BRAF mutation is the c.1799T > A point mutation leading to single amino acid substitution V600E. Detection of this BRAF mutation in colon carcinoma has potential as a prognostic marker and also a treatment target for new BRAF inhibitors, such as vemurafenib. 2, 3 Moreover, the presence of V600E mutations might indicate resistance to anti-epidermal growth factor receptor (EGFR) therapy as seen in KRAS mutants, which are unlikely to benefit from EGFR inhibitor treatment. 4, 5 Thus, KRAS and BRAF testing before such treatment would help target these expensive treatments to appropriate patients. 6 However, the Evaluation of Genomic Applications in Practice and Prevention Working Group (EGAPP) recently stated that the power of BRAF V600E testing to guide anti-EGFR therapy is probably low. 7 Various molecular genetic assays have been used to identify BRAF V600E mutation. [8] [9] [10] More recently, a BRAF V600E mutant-specific monoclonal antibody (clone VE1) was introduced and used to identify this BRAF-mutant protein in archival formalin-fixed paraffin-embedded (FFPE) tissue specimens from different malignancies including colon carcinoma. 11, 12 Some studies have reported near to complete concordance between immunohistochemically identified BRAF V600E mutant expression and detection of V600E mutation in colon carcinomas. 9, [13] [14] [15] [16] However, 1 study concluded that immunohistochemistry with VE1 antibody is not a useful surrogate for genotyping in colorectal carcinomas. 17 The aim of this study was to further evaluate the sensitivity and specificity of V600E mutant-specific antibody (VE1) to detect BRAF V600E mutation in colon cancers thoroughly analyzed for BRAF and RAS mutations, as the latter are mutually exclusive with BRAF and thus offer parallel evidence for BRAF gene status.
MATERIALS AND METHODS

Study Material and Design
A total of 113 anonymized and annotated colon carcinoma specimens from Europe and United States were selected for this study on the basis of availability of representative material. Following microdissection, the tumor tissue was processed for DNA extraction and immunohistochemical studies. Immunostaining analyses were performed in the Laboratory of Pathology (LP), whereas screening for BRAF mutations was performed independently in 3 laboratories using 4 different analytical systems: Sanger sequencing (LP), the Cobas 4800 BRAF V600 Mutation Test (Department of Biology and Genetics, Medical University of Gdansk, Poland), and BRAF allele-specific polymerase chain reaction (PCR), and quantitative PCR (qPCR) (Department of Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland). Multiple methods for mutation analysis were used to ensure comprehensive detection of the BRAF mutation status. All immunohistochemical and mutation analysis studies were conducted blindly without knowledge of results from the other studies.
Immunohistochemistry
Multitissue blocks containing 30 to 50 colon carcinomas were prepared as previously described. 18 Immunostaining was performed with Leica Bond-Max automatic immunostainer (Leica, Bannockburn, IL) following 25 minutes incubation at room temperature in Bond Epitope Retrieval Solution 1 (Leica Biosystems; Catalog No. AR9961). Expression of the BRAF V600Emutant protein was evaluated immunohistochemically using a mouse monoclonal VE1 antibody (Spring Bioscience, Pleasanton, CA) diluted 1:200, with 30 minutes incubation at room temperature. The dilution selected was the lowest dilution yielding a strong signal in a series of positive controls (V600E mutant tumors, including malignant melanomas) while giving no staining or a weak blush in negative controls. The polymer detection was performed for 15 minutes, on the basis of the observation that a shorter detection time (8 min) did not significantly reduce false-positive staining in colon carcinoma specimens (similar positivity commonly remained in smooth muscle and occasionally in normal mucosa). The immunostaining was scored arbitrarily as negative (no staining), weak (pale staining significantly differing from background), moderately positive (more than pale, with tinctorial quality intermediate between weak and strong), and strongly positive (deep, golden brown staining).
Expression of DNA mismatch-repair proteins was evaluated using antibodies to MLH1, MSH2, and MSH6 proteins from Cell Marque (http://www.cellmarque.com) and PMS2 from BD Pharmingen (http://www.bdbio sciences.com). MLH1 was diluted 1:600, MSH 1:500, MSH6 1:80, and PMS2 1:200. Nuclear staining was scored as positive or negative, with the presence of positive normal cell components in each case.
Tissue Selection and DNA Extraction
FFPE tumor samples were selected for DNA extraction by enriching the tumor content by hematoxylin and eosin-stained slide-guided microdissection. Ten 5mm-thick sections were deparaffinized with xylene, washed twice in ethanol, lyophilized, and incubated with 10 mg/mL proteinase K (Roche Diagnostics, Indianapolis, IN) in Hirt-Buffer at 551C for 24 hours. Subsequently, DNA was recovered using the Maxwell 16 robotic system and DNA IQ Casework Pro Kit for Maxwell 16 (Promega, Madison, WI) as previously reported. 19 PCR Amplification for Sanger Sequencing BRAF codon 600 flanking sequences were PCR amplified using the following primers: 5 0 TCTTCATG AAGACCTCACAG 3 0 and 5 0 AGCCTCAATTCTTAC CATCC 3 0 . PCR amplifications were performed with AmpliTaq Gold DNA polymerase (Applied Biosystems, Roche, Branchburg, NJ) following the standard 3-temperature PCR protocol, with denaturing at 941C, annealing at 501C, and extension at 721C. PCR reactions (50 mL) were evaluated on agarose gels. The 155 bp PCR products were extracted using QIAquick Gel Extraction Kit (http://www.qiagen.com) and submitted for sequencing with the above-mentioned primers. Sanger sequencing of PCR amplification products was performed by Mac-rogenUSA, Rockville, MD. Obtained sequences were analyzed and aligned with BRAF reference sequence, NM_004333.4 (http://www.ncbi.nlm.nih.gov).
Cases apparently negative for BRAF V600E were evaluated for alternative mutations in KRAS codons 12, 13, 61, and 146 and NRAS codons 12, 13, and 61 by PCR amplification and direct Sanger sequencing of PCR amplification products. Primer sequences and PCR conditions are listed in Table 1 .
The Cobas 4800 BRAF V600 Mutation Test
Mutational analysis was performed using the Cobas 4800 BRAF V600 Mutation Test and Cobas 4800 system according to the manufacturer's protocol obtained from Roche Molecular Systems, NJ (http://www. cobasbraftest.com).
BRAF V600 Allele-specific PCR BRAF V600 allele-specific PCR was performed using the wild-type (WT)-specific BRAFek15f 5 0 TCAT AATGCTTGCTCTGATAGGA 3 0 and BRAFek15r 5 0 GGCCAAAAATTTAATCAGTGGA 3 0 primers and V600E mutation-specific BRAFek15mutA 5 0 GGT GATTTTGGTCTAGCTACAGA 3 0 primer. PCR conditions consisted of one 10-minute cycle at 951C, 35 cycles of 15 seconds at 951C, and 1-minute incubation at 601C. Appropriate positive and negative controls were included in each experiment. PCR products were analyzed using MultiNA Microchip Electrophoresis System following manufacturer instructions (Shimadzu, Japan). The 224and 126-bp PCR amplification products represented WT and mutant BRAF alleles, respectively.
BRAF V600 qPCR
qPCR by TaqMan assay targeting 68 bp of BRAF exon 15 was performed using Rotor-Gene Q (Qiagen, Synge-Biotech, Poland) with forward 5 0 AGACCTCACAGTA AAAATAGGTGATTTTGG 3 0 and reverse 5 0 GATGGG ACCCACTCCATCG 3 0 primers. The cycling conditions consisted of one 10-minute cycle at 951C, 50 cycles of 10 seconds at 951C, and 30 seconds of incubation at 671C. Appropriate positive and negative controls were included in each experiment. BRAF V600E mutant-specific probe (6FAM-TAGCTACAGAGAAATC-MG-BNFQ) and BRAF-WT allele-specific probe (VIC-CTAGCTAC AGTGAAATC-MGB-NFQ) were used. 20 The qPCR data were analyzed using Rotor-Gene Q software version 2.2.3.
RESULTS
Clinicopathologic Data
A total of 113 colonic adenocarcinomas diagnosed in 52 men and 61 women were analyzed. The median and mean ages of colon cancer patients were identical-68 years. The 95 primary tumors were from the cecum (n = 27), ascending colon (n = 7), hepatic flexure (n = 3), transverse colon (n = 8), splenic flexure (n = 3), descending colon (n = 3), sigmoid colon (n = 32), and unspecified location in the colon (n = 12). Eighteen metastatic tumors were from the liver (n = 9), lung (n = 3), brain (n = 2), and ovary, pancreas, pelvis, and small bowel mesentery (n = 1 each). Most tumors were gland-forming adenocarcinomas, but 12 were mucinous carcinomas with extensive extracellular mucin production, and 3 tumors were composed of solid sheets of epithelial cells and scant fibrous stroma (medullary type of histology).
Comparison of Immunohistochemical and Molecular Genetic Studies
Summary of the results on VE1 immunohistochemistry in relation to BRAF V600E mutation and mismatch-repair status is shown in Table 2 .
Twenty-four of 45 colon carcinomas with any VE1 positivity (strong, moderate, or weak) and 3 of 67 VE1negative cases were V600E mutants. However, 23 of 34 cases with strong to moderate VE1 immunoreactivity were V600E mutants, whereas only 1 of 12 tumors with weak VE1 immunostaining carried the V600E mutation.
The sensitivity for BRAF mutation detection with the VE1 antibody was 85% (23 of 27) if strong to moderate reaction was scored as a positive result and 89% (24 of 27) if any (including weak) immunostaining was interpreted as a positive result. The specificity of this assay was 68% if only strong to moderate staining was considered positive. However, it declined to 51% if any positive staining was considered to indicate BRAF V600E mutant expression.
Most cases (20/26, 77%) with loss of MLH1/PMS2 expression carried BRAF V600E mutation, and 2 were KRAS exon 12 mutants. In addition, 1 KRAS exon 12 mutant had loss of MSH2/MSH6 expression. BRAF immunohistochemistry was concordant with molecular results in 18 of 20 cases with loss of MLH1/PMS2 expression. Two tumors with loss of MLH1/PMS2 expression and BRAF V600E mutation lacked VE1 immunoreactivity. Moreover, 2 KRAS exon 12 mutants with loss of MLH1/PMS2 expression showed false-positive BRAF immunostaining.
Immunohistochemical Studies
Thirty-four colon carcinomas showed strong (n = 2) to moderate positivity with VE1 antibody, whereas 67 were entirely negative. The remaining 12 tumors displayed weak staining. Mismatch-repair-deficient status was detected in 28 tumors. There were 26 cases with loss of MLH1/PMS2 and 2 tumors with loss of MSH2/MSH6. In addition, colonic smooth muscle commonly showed variable granular VE1 immunoreactivity, and colonic mucosa was occasionally positive, usually weakly. Representative examples of immunostaining are shown in Figures 1 and 2 . 
KRAS and NRAS Mutations
Clinicopathologic and Molecular Profile of False-positive and False-negative Cases
The clinicopathologic features of discordant, VE1 false-positive and false-negative cases are summarized in Tables 3 and 4 . BRAF-WT colon carcinomas with strong to moderate VE1 staining consisted of 7 primary and 4 metastatic colon carcinomas. Three of these tumors showed mismatch-repair deficiency. KRAS codon 12 or 13 mutations were identified in 8 cases. Three VE1-negative and 1 with weakly VE1-positive colon carcinomas carried a BRAF V600E mutation. Three of these tumors were from the right colon (cecum = 1, ascending colon = 2) and 1 from the sigmoid colon. Mismatch-repair gene deficiency was documented in 3 cases including sigmoid tumor.
DISCUSSION
Recently, a BRAF V600E mutant-specific antibody VE1 became available for immunohistochemical screening of such BRAF-mutant tumors. 11 Initial studies showed that this antibody could identify BRAF V600E mutants in a spectrum of cancers, including colorectal carcinomas. 21 Because V600E represents a great majority of BRAF mutations in colon carcinoma, 1 immunohistochemistry of the V600E mutant protein could be an alternative mutation detection method to molecular genetic assays. However, a recent study challenged the specificity of VE1 antibody and its use for the immunohistochemical evaluation of BRAF V600E mutants in colon carcinomas. 17 In the present study, a cohort of 113 colon carcinomas was analyzed immunohistochemically for the expression of BRAF V600E mutant protein and the status of BRAF V600E and other BRAF exon 15 mutations by molecular genetic techniques.
Our results showed that sensitivity and specificity of VE1 immunohistochemistry for the V600E mutant were 85% and 68%, respectively, provided that only strong to moderately positive staining was considered positive. On the basis of our results on a highly sensitive detection system such as Leica Bond-Max under the described conditions, weak staining should not be considered positive, as this lowers the specificity to 51% without significant improvement in the detection sensitivity. Our results differ from those of 2 previous studies showing 100% sensitivity and 100% specificity of VE1 immunohistochemistry in the diagnosis of colon carcinoma BRAF V600E mutants. 14, 15 However, our results show almost 2 times higher sensitivity than those reported in another study. 17 A significant number (11 of 86) of BRAF V600E mutation-negative (BRAF-WT) tumors showed strong to moderate VE1 staining. The negative results of mutation analysis were confirmed by multiple tests including addi-tional evaluation of DNA extracted from microdissected VE1-positive tumor cell islands. The clinicopathologic and molecular genetic profiles of these false-positive cases were similar to those of VE1-negative BRAF-WT colon carcinomas. Seventy-three percent of BRAF-WT tumors with strong to moderate VE1 staining, including 3 mismatchdeficient tumors, carried KRAS mutations. As KRAS and BRAF mutations are mutually exclusive in colon carcinoma, 22 these tumors clearly represent cases with false-positive VE1 immunohistochemical staining. A recent study of 52 colorectal carcinomas reported weak cytoplasmic staining in 17% of analyzed cases including 3 KRAS mutants. 17 At present, the explanation for false-positive VE1 staining remains unknown. However, such a problem seems to occur with different immunohistochemical detection systems and platforms including manual staining and automated Dako, Leica Bond, and Ventana stainers. 16, 17, 23 Granular cytoplasmic VE1 immunostaining seen in normal gastrointestinal smooth muscle and nuclear positivity in normal mucosa cells in our study were also reported by others indicating incomplete specificity of the VE1 antibody to the BRAF V600E mutant protein and existence of cross-reactivity with other epitopes apparently present even in normal tissues. 14, 16, 23 In this study, strong false-positive VE1 staining was seen in 2 colon carcinomas. Two colon carcinomas with strong VE1 staining and lack of BRAF V600E mutation were also previously reported. 13, 23 In addition, 1 study detailed 3 thyroid papillary carcinomas with strong VE1 immunoreactivity unassociated with BRAF mutations. 24 Moreover, recent studies showed diffuse, strong VE1 immunoreactivity in pituitary adenomas unassociated with the BRAF V600E mutation. 25, 26 Therefore, occasionally encountered strong false-positive staining with the VE1 antibody in colon carcinomas could also represent "true immunoreactivity" with unknown homologous epitopes.
In this study, 4 BRAF V600E mutants revealed either no or weak immunohistochemical staining with VE1 antibody representing false-negative results. Clinical characteristics of these tumors, female sex, the proximal colonic location, and mismatch-repair gene deficiency were compatible with the characteristics of sporadic microsatellite-unstable colon cancer. 27 A recent series reported 5 BRAF-mutant colorectal carcinomas with negative VE1 immunohistochemistry. 17 Decreased immunoreactivity due to low level of BRAF mutant expression or suboptimal antigen preservation during specimen processing may explain these false-negative results. Previous studies showed that VE1 immunohistochemistry coupled with other tests might be useful for Lynch syndrome screening, as BRAF mutation shows positive correlation with mismatch-repair deficiency in sporadic microsatellite-unstable colorectal cancer. 13, 16, 23 In this study, 90% of microsatellite-unstable tumors with BRAF V600E mutations were identified by positive VE1 staining, although 2 false-negative and 2 false-positive cases were seen as well. Thus, use of BRAF V600E mutant immunohistochemistry might be useful for initial screening for Lynch syndrome, although it should be followed by molecular genetic testing.
The detection of small tumor foci with BRAF V600E mutation could be assisted by immunohistochemical testing. Furthermore, immunohistochemical approach could also be useful in cases with low numbers of tumor cells allowing selection of material for molecular testing by methods such as laser capture microdissection. Theoretically, evaluation of BRAF mutation status in cases with significant DNA degradation might also benefit from the immunohistochemical approach, although molecular assays targeting BRAF V600E mutation are often based on short amplicons relatively well preserved even in significantly degraded DNA.
Targeted therapy of colon carcinoma depends on precise tumor genotyping and consists of simultaneous evaluation of numerous genes from RAS/RAF/MAPK and other signaling pathways involved in tumor progression. 4 Recently developed low-cost sequencing platforms allow concurrent sequencing of multiple targets. 28 This may diminish the role of BRAF V600E immunohistochemistry in tailoring treatment for individual patients, especially considering the potential false-positive and false-negative results.
In summary, our study showed that VE1 immunohistochemistry can identify colon cancer BRAF V600E mutants with relatively high sensitivity and moderate specificity. This antibody may be helpful in screening for BRAF-mutant colon carcinomas, but the BRAF mutation status should always be verified by molecular genetic studies.
